PRIMA-1 cytotoxicity was shown to correlate with the degradation of mutant P53 in breast cancer cells, leading to speculate that, in these cells, the sensitivity to PRIMA-1 could depend on the abolition of GOF activity of the mutant P53, through a protein degradation pathway induced by the drug [91]. The gene discussed is TP53; the disease is breast carcinoma.